Journal profile · Peripheral Vascular Disease
Clinical and Experimental Hypertension
ISSN 1064-1963 · eISSN 1525-6006 · Informa Healthcare · UNITED STATES · Bimonthly · Founded 1993
Clinical and Experimental Hypertension: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 6.81; JCR Q1 (journal website); fully open access; APC about USD 2,990; median 80 days to acceptance (94 articles, last 24 months); community-reported acceptance: easy; 52 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical and Experimental Hypertension is published by Informa Healthcare and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Blood Pressure and Hypertension Studies, Hormonal Regulation and Hypertension and Renin-Angiotensin System Studies, together about 36.7% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Please note that Clinical and Experimental Hypertension converted to a full Open Access journal from Volume 45 (2023). Previous volumes will continue to provide access through a Pay to Read model. Aims & Scope Serving as an international forum for the exchange of state-of-the-art scientific and clinical information on all aspects of human and animal hypertension, this authoritative journal publishes full articles as well as solicited and unsolicited reviews and commentaries that extend current understanding as well as facilitate the timely and successful detection, management, control, and prevention of hypertension-related conditions. Features special issues covering proceedings of symposia on hypertension research! Clinical and Experimental Hypertension maintains a rapid communications format that brings readers new and important research and findings in a prompt and reliable publication schedule in areas, including antihypertensive agents circulatory control drug development and application etiology mechanisms of action neurogenic mechanisms pathophysiology pharmacological and nonpharmacological treatment and much more! Please note, from 2023 the Print ISSN is not in active use as this journal is no longer published in print.
From the journal's Aims & Scope
Research area (LetPub): Peripheral Vascular Disease
Editor-in-chief Chengming FanPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Blood Pressure and Hypertension StudiesMedicine16.3%
- Hormonal Regulation and HypertensionMedicine11.3%
- Renin-Angiotensin System StudiesMedicine9.2%
- Heart Rate Variability and Autonomic ControlMedicine8.9%
- Sodium Intake and HealthNursing6.1%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology5.3%
- Cardiovascular Health and Disease PreventionMedicine4.7%
- Nitric Oxide and Endothelin EffectsMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Peripheral Vascular Disease | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Peripheral Vascular Disease | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Peripheral Vascular Disease | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
- CiteScore Q1 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbaseCAB AbstractsCurrent ContentsPublisher website
Other: E-psyche, MetaPress - Abstracts in Anthropology (Online), Personal Alert (E-mail)
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.81LetPub ·
- Impact factor (publisher) 2025
- 6.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.8Publisher website ·
- CiteScore 2026-06
- 6.5LetPub ·
- CiteScore (publisher) 2025
- 6.5Publisher website ·
- SJR 2026-06
- 0.93LetPub ·
- SJR (publisher) 2025
- 0.93Publisher website ·
- SNIP 2026-06
- 0.92LetPub ·
- SNIP (publisher) 2025
- 0.92Publisher website ·
- h-index
- 45LetPub ·
- h-index
- 76OpenAlex ·
- i10-index
- 2,117OpenAlex ·
- 2-year mean citedness
- 4.39OpenAlex ·
- Self-citation rate
- 1.5%LetPub ·
- Share of gold OA articles
- 99.32%LetPub ·
Volume
- Articles per year
- 45LetPub ·
- Downloads per year (publisher)
- 209,000Publisher website ·
Articles by year OpenAlex count · 4,498 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 41 | 41 | 31 |
| 2025 | 52 | 52 | 155 |
| 2024 | 26 | 26 | 336 |
| 2023 | 75 | 75 | 1,386 |
| 2022 | 71 | 9 | 418 |
| 2021 | 84 | 16 | 696 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
80 daysMedian, submission to acceptance · P25–P75 55 days – 126 days
- Acceptance to online
- median 12 days (94 articles)
- Submission to online
- median 100 days
- Sample
- 94 articles with submission and acceptance dates (97 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Acceptance rate (publisher)
- 18%Publisher website ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 40 daysPublisher website ·
- Acceptance to publication
- 10 daysPublisher website ·
- Submission to publication (journal-reported)
- about 7 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,990 / GBP 2,392 / EUR 2,875 / AUD 4,165 | Yes | CC BY, CC BY-NC | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open access
Open access journal; only publishes open access articles. Model summary
Clinical and Experimental Hypertension is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers,…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Informa Healthcare
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1993
- ISSN
- 1064-1963
- Electronic ISSN
- 1525-6006
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Clinical and Experimental Hypertension
What CAS zone is Clinical and Experimental Hypertension in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical and Experimental Hypertension is in Zone 4 of Medicine, and in Zone 4 of the minor category Peripheral Vascular Disease / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical and Experimental Hypertension?
The latest impact factor listed by LetPub is 6.81; CiteScore 6.5, h-index 76.
How long does peer review take at Clinical and Experimental Hypertension?
Based on the dates recorded on 94 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 80 days (interquartile range 55–126 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Easy”; the journal's website gives an acceptance rate of 18%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Clinical and Experimental Hypertension in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Clinical and Experimental Hypertension?
According to LetPub and DOAJ records, Clinical and Experimental Hypertension is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase, CAB Abstracts and Current Contents; that list has not been checked against each database.
Is Clinical and Experimental Hypertension open access, and what is the APC?
Clinical and Experimental Hypertension is a fully open-access journal. APC about USD 2,990.
Sources and updates
The facts on this page come from LetPub, Publisher website, DOAJ, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .